Related Experiment Videos
A dose-ranging study of rapacuronium in pediatric patients.
G H Meakin1, O A Meretoja, J Motsch
1Department of Anesthesia, the University of Manchester, United Kingdom. george.meakin@man.ac.uk
Anesthesiology
|April 8, 2000
Summary
This study found that 1.5 mg/kg rapacuronium in infants and 2.0 mg/kg in children provide good tracheal intubation conditions within 60 seconds. Rapacuronium offers a short duration of action for pediatric anesthesia.
Area of Science:
- Anesthesiology
- Pediatric Pharmacology
- Clinical Trials
Background:
- Evaluating new anesthetic agents is crucial for pediatric patient care.
- Rapacuronium is a novel rapid-onset, short-acting neuromuscular blocking drug.
- Determining optimal dosing for tracheal intubation in pediatric populations is essential.
Purpose of the Study:
- To establish the effective dose of rapacuronium for rapid tracheal intubation in infants and children.
- To assess the safety and efficacy of rapacuronium in diverse pediatric age groups.
Main Methods:
- A dose-ranging study involving 165 infants and children (under 12 years).
- Administration of five different doses of rapacuronium (0.5-2.5 mg/kg) post-induction.
- Assessment of intubating conditions using a standardized scale and monitoring neuromuscular transmission.
Main Results:
- Satisfactory intubation conditions achieved at 60s with ≥1.5 mg/kg in infants and ≥2.0 mg/kg in children.
- Rapacuronium's duration of action was dose- and age-dependent, generally short.
- Adverse events were infrequent and mild, including bronchospasm and tachycardia.
Conclusions:
- Doses of 1.5 mg/kg (infants) and 2.0 mg/kg (children) of rapacuronium provide effective tracheal intubation.
- Rapacuronium demonstrates a favorable short duration of action for pediatric anesthesia.
- The drug is associated with a low incidence of minor adverse events.